Skip to main content Skip to main navigation menu Skip to site footer

Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism rather than homocysteine increase the risk of ischemic stroke-associated executive dysfunction


Background: An executive dysfunction is a form of cognitive impairment commonly found in ischemic stroke patients with a significant impact on the patients' quality of life. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and homocysteine ​​are considered important risk factors for stroke and various forms of cognitive dysfunction. This study aimed to investigate the association between the MTHFR C677T polymorphism and serum homocysteine levels and the risk of ischemic stroke-associated executive dysfunction.

Method: 87 ischemic stroke patients within the first three months of stroke onset in West Nusa Tenggara General Hospital, Siti Hajar Hospital, and Mataram General Hospital were recruited. Serum homocysteine levels were assessed using ELISA. The MTHFR C677T polymorphism was analyzed using the PCR-RFLP procedure. The executive function of the patients was evaluated using Trail Making Test Part-B, verbal fluency, and backward digit span tests.

Results: The mean age of the subjects was 54.1 years. CT scan data revealed that 78.2% of subjects had a small infarct size. The MTHFR C677T polymorphism frequency was 25.3%, consisting of 2.3% homozygous and 23.0% heterozygous mutants. Multivariate logistic regression analysis showed that patients with MTHFR C677T polymorphism were more likely to have executive dysfunction than those with the wild-type genotype of the MTHFR gene (OR 4.53, 95% CI 1.06–19.27, p = 0.041). However, patients with hyperhomocysteinemia (≥13 μmol/l) were not associated with an increased risk of executive dysfunction.

Conclusion: The MTHFR C677T polymorphism was the risk factor for ischemic stroke executive dysfunction.


  1. Jaillard A, Naegele B, Trabucco-Miguel S, LeBas JF, Hommel M. Hidden dysfunctioning in subacute stroke. Stroke. 2009;40(7):2473–9.
  2. Pinter D, Enzinger C, Gattringer T, Eppinger S, Niederkorn K, Horner S, et al. Prevalence and short-term changes of cognitive dysfunction in young ischaemic stroke patients. Eur J Neurol. 2019;26(5):727–32.
  3. Cumming TB, Marshall RS, Lazar RM. Stroke, cognitive deficits, and rehabilitation: still an incomplete picture. Int J Stroke. 2013;8:38–45.
  4. Rabinovici GD, Stephens ML, Possin KL. Executive dysfunction. Contin (Minneap Minn). 2015;21(3 Behavioral Neurology and Neuropsychiatry):646–59.
  5. Poulin V, Korner-Bitensky N, Dawson DR, Bherer L. Efficacy of executive function interventions after stroke: a systematic review. Top Stroke Rehabil. 2012;19(2):158–71.
  6. Lo JW, Crawford JD, Desmond DW, Godefroy O, Jokinen H, Mahinrad S, et al. Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology. 2019;93(24):e2257--e2271.
  7. Obaid M, Douiri A, Flach C, Prasad V, Marshall I. Can we prevent poststroke cognitive impairment? An umbrella review of risk factors and treatments. BMJ Open. 2020;10(9):e037982.
  8. Zhang T, Jiang Y, Zhang S, Tie T, Cheng Y, Su X, et al. The association between homocysteine and ischemic stroke subtypes in Chinese. Medicine (Baltimore). 2020;99(12):e19467.
  9. Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a risk factor for vascular contributions to cognitive impairment and dementia. Front Aging Neurosci. 2018;10:350.
  10. Moretti R, Caruso P. The controversial role of homocysteine in neurology : from labs to clinical practice. Int J Mol Sci. 2019;20:231.
  11. Camerino I, Sierpowska J, Reid A, Meyer NH, Tuladhar AM, Kessels RPC, et al. White matter hyperintensities at critical crossroads for executive function and verbal abilities in small vessel disease. Hum Brain Mapp. 2021;42(4):993–1002.
  12. Barroso M, Handy DE, Castro R. The link between hyperhomocysteinemia and hypomethylation: implications for cardiovascular disease. J Inborn Errors Metab Screen. 2017;5:1–15.
  13. Cajavilca CE, Gadhia RR, Roman GC. MTHFR Gene Mutations Correlate with White Matter Disease Burden and Predict Cerebrovascular Disease and Dementia. Brain Sci. 2019;9(9):211.
  14. Hou J, Zeng X, Xie Y, Wu H, Zhao P. Genetic polymorphisms of methylenetetrahydrofolate reductase C677T and risk of ischemic stroke in a southern Chinese Hakka population. Medicine (Baltimore). 2018;97(51):e13645.
  15. Arina CA, Amir D, Siregar Y, Sembiring RJ. The Role of Polymorphism Gen Methylene Tetra Hydrofolate Reductase ( MTHFR ) C677T in Ischaemic Stroke Patients with and Without Hypertension. Open Access Maced J Med Sci. 2019;7(1):29–32.
  16. Pramukarso DT, Faradz SMH, Sari S, Hadisaputro S. Association between methylenetetrahydrofolate reductase (MTHFR) polymorphism and carotid intima medial thickness progression in post ischaemic stroke patient. Ann Transl Med. 2015;3(21):324.
  17. Liew S-C, Gupta E Das. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015;58(1):1–10.
  18. Rutten-Jacobs LCA, Traylor M, Adib-Samii P, Thijs V, Sudlow C, Rothwell PM, et al. Association of MTHFR C677T genotype with ischemic stroke is confined to cerebral small vessel disease subtype. Stroke. 2016;47(3):646–51.
  19. Kauranen T, Laari S, Turunen K, Mustanoja S, Baumann P, Poutiainen E. The cognitive burden of stroke emerges even with an intact NIH Stroke Scale Score : a cohort study. J Neurol Neurosurg Psychiatry. 2014;85:295–9.
  20. Muangpaisan W, Intalapaporn S, Assantachai P. Digit span and verbal fluency tests in patients with mild cognitive impairment and normal subjects in Thai-community. J Med Assoc Thail. 2010;93(2):224–30.
  21. Roy M, Molnar F. Systematic review of the evidence for Trails B cut-off scores in assessing fitness-to-drive. Can Geriatr J. 2013;16(3):120–42.
  22. Roman GC, Mancera-Paez O, Bernal C. Epigenetic factors in late-onset Alzheimer's disease: MTHFR and CTH gene polymorphisms, metabolic transsulfuration and methylation pathways, and B vitamins. Int J Mol Sci. 2019;20:319.
  23. Lu H, Liu X, Deng Y, Qing H. DNA methylation, a hand behind neurodegenerative diseases. Front Aging Neurosci. 2013;5:85.
  24. Kerins DM, Koury MJ, Capdevila A, Rana S, Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr. 2001;74(6):723–9.
  25. Wagner C, Koury MJ. S-Adenosylhomocysteine - a better indicator of vascular disease than homocysteine? Am J Clin Nutr. 2007;86(6):1581–5.
  26. Borrione P, Fossati C. Hyperhomocysteinemia and its role in cognitive impairment and Alzheimer's disease : recent updates from the literature. Endocrinol Metab. 2017;1(1):1.
  27. Antonaros F, Olivucci G, Cicchini E, Ramacieri G, Pelleri MC, Vitale L, et al. MTHFR C677T polymorphism analysis: A simple, effective restriction enzyme ‐ based method improving previous protocols. Mol Genet Genomic Med. 2019;7:e628.
  28. Kessels RPC, Eikelboom WS, Schaapsmeerders P, Maaijwee NAM, Arntz RM, van Dijk EJ, et al. Effect of formal education on vascular cognitive impairment after stroke: a meta-analysis and study in young-stroke patients. J Int Neuropsychol Soc. 2017;23:223–38.
  29. Chen X, Duan L, Han Y, Tian L, Dai Q, Wang S, et al. Predictors for vascular cognitive impairment in stroke patients. BMC Neurol. 2016;16(1):115.
  30. Alia C, Spalletti C, Lai S, Panarese A, Lamola G, Bertolucci F, et al. Neuroplastic changes following brain ischemia and their contribution to stroke recovery: novel approaches in neurorehabilitation. Front Cell Neurosci. 2017;11:76.
  31. Dabrowski J, Czajka A, Zielinska-Turek J, Jaroszynski J, Furtak-Niczyporuk M, Mela A, et al. Brain functional reserve in the context of neuroplasticity after stroke. Neural Plast. 2019;2019:9708905.
  32. Barulli D, Stern Y. Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve. Trends Cogn Sci. 2013;17(10):502–9.
  33. Kluwe-Schiavon B, Sanvicente-Vieira B, Viola TW, Souza LSAE, Rigoli MM, Fonseca RP, et al. rehabilitation of executive functions: implications and strategies. Av en Psicol Latinoam. 2013;31(1):110–20.
  34. Jadavji NM, Emmerson JT, MacFarlane AJ, Willmore WG, Smith PD. B-vitamin and choline supplementation increases neuroplasticity and recovery after stroke. Neurobiol Dis. 2017;103:89–100.
  35. Pascoe MC, Ski CF, Thompson DR, Linden T. Serum cholesterol, body mass index and smoking status do not predict long-term cognitive impairment in stroke elderly patients. J Neurol Sci. 2019;406:116476.
  36. Durazzo TC, Meyerhoff DJ, Nixon SJ. Chronic cigarette smoking: implications for neurocognition and brain neurobiology. Int J Environ Res Public Health. 2010;7(10):3760–91.
  37. Yang Y, Shields GS, Guo C, Liu Y. Executive function performance in obesity and overweight individuals: A meta-analysis and review. Neurosci Biobehav Rev. 2017;84:225–44.

How to Cite

Harahap, H. S., Akbar, M., Bintang, A. K., Tammasse, J., & Zainuddin, A. A. (2022). Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism rather than homocysteine increase the risk of ischemic stroke-associated executive dysfunction. Bali Medical Journal, 11(1), 443–450.




Search Panel

Herpan Syafii Harahap
Google Scholar
BMJ Journal

Muhammad Akbar
Google Scholar
BMJ Journal

Andi Kurnia Bintang
Google Scholar
BMJ Journal

Jumraini Tammasse
Google Scholar
BMJ Journal

Andi Alfian Zainuddin
Google Scholar
BMJ Journal